

aaaai.org

AAAAI's quarterly digital membership magazine

Welcome Back to the AAAAI Annual Meeting



Get the details for this year's event starting on page 8.

WHAT IS BEHIND CHRONIC COUGH?

Visit AAAAI **Merck booth #445** to explore emerging science and common clinical presentations of chronic cough.

And join us for a Merck-sponsored non-CME program to learn more about chronic cough.

Understanding Chronic Cough: Patient Presentation and Assessment

Topics:

- Discuss patient cases and understand patient presentation of chronic cough
- Review clinical guidelines
- Understand potential mechanisms of disease in chronic cough

Join this live program on:

Saturday February 26, 2022

6:30 – 8:00 PM MT 6:30 – 7 pm: Registration 7 – 8 pm: Educational session and dinner

Sheraton Phoenix Downtown 340 N 3rd St, Phoenix, AZ Valley of the Sun Ballroom E, 2nd Level

If you are interested in additional information about chronic cough, scan this QR code with your smartphone camera or visit **behindthecough.com**



This medical education program is intended for health care professionals and health care business professionals of the United States, its territories, and Puerto Rico. Merck is sponsoring this program and the speaker is presenting on behalf of Merck. The program is a non-CME event. Information presented in this program is consistent with FDA guidelines.

This program is not sponsored or programmed by the AAAAI.



Copyright © 2022 Merck & Co., Inc., Kenilworth, NJ, USA and its affiliates. All rights reserved. US-OGM-00846 02/22



aaaai.org

Board of Directors President

Giselle S. Mosnaim, MD, MS, FAAAAI

President-Elect David A. Khan, MD, FAAAAI

Secretary-Treasurer Jonathan A. Bernstein, MD, FAAAAI

Immediate Past President Mary Beth Fasano, MD, MSPH, FAAAAI

At-Large Members

Stuart L. Abramson, MD, PhD, AE-C, FAAAAI Leonard B. Bacharier, MD, FAAAAI Paula J. Busse, MD, FAAAAI Timothy J. Craig, DO, FAAAAI Carla M. Davis, MD, FAAAAI Carla M. Davis, MD, FAAAAI Denise A. DiPrimio-Kalman, DO, FAAAAI Tamara T. Perry, MD, FAAAAI Wanda Phipatanakul, MD, MS, FAAAAI Thanai Pongdee, MD, FAAAAI Sarbjit (Romi) Saini, MD, FAAAAI Frank S. Virant, MD, FAAAAI Paul V. Williams, MD, FAAAAI

IMPACT Editorial Team

Executive Vice President Thomas A. Fleisher, MD, FAAAAI

Executive Director Rebecca Brandt, CAE

Publication Manager April Presnell

For address changes, contact the AAAAI, 555 E. Wells Street, Suite 1100, Milwaukee, WI 53202-3823 telephone (414) 272-6071 fax (414) 272-6070 email info@aaaai.org

Copyright ©2022 by the American Academy of Allergy, Asthma & Immunology.

The American Academy of Allergy, Asthma & Immunology does not endorse products or services from related industries, associations or organizations and reserves the right to change any copy that may be inconsistent with this policy. As such, any external advertisements that appear in *IMPACT* are not an endorsement of their products or services.

IMPACT (ISSN 1094-4745) is published quarterly by the American Academy of Allergy, Asthma & Immunology (AAAAI). It reports news as it affects the specialty, practices, patients, and the profession; and provides information on AAAAI programs and activities.



8







President's Message

4-5

VV

- What's New at aaaai.org
 Featured CME Opportunities
- 8-11 Your Guide to the 2022 AAAAI Annual Meeting
 - 14 Join Us for These Social Events at the 2022 Annual Meeting
 - 16 Explore Phoenix During the 2022 AAAAI Annual Meeting

Contents

- 17 AAAAI Officially Launches New Gold Open Access Journal
- **18** Get Mentored Career Advice at the Faculty Development Program
- 20-21 What the Interest Sections Are Doing for AAAAI Members
 - 23 Insights from Young Investigator Caroline L. Sokol, MD, PhD, FAAAAI

Don't Miss These Upcoming Sponsored Webinars

24-25 Meet the New Members of the AAAAI Board of Directors

- 27 In Brief
- 29 November 2021 Board of Directors Meeting Summary

President's Message

Giselle S. Mosnaim, MD, MS, FAAAAI 2021–2022 AAAAI President



Dear Colleagues,

As I near the end of my term as AAAAI President, I have been reflecting on what has been the most rewarding part of this experience. First, I am grateful to have had the opportunity to work with talented, passionate, and committed leaders in allergy and immunology, whom I may have never met otherwise. The other most rewarding aspect is that I look at leadership as a personal journey in which you take risks. You step outside of your

comfort zone, you learn from your successes and failures, and you grow as an individual. I want to continue this lifelong journey and also bring others along with me—and I would love to see each of them succeed as well.

Being outside of your comfort zone, learning from successes and failures, and growing as an individual are things all of us have experienced, especially due to the COVID-19 pandemic and its continued impact on our personal and professional lives. I will admit it was challenging at first to develop my own leadership style and work with the AAAAI Board over Zoom for our regular meetings, as opposed to being able to connect with people in person. And like many of you, I was also struggling with priorities, and how to balance supporting our patients and our healthcare professionals during the daily struggles with a pandemic, while at the same time working toward achieving the presidential initiatives that I set forth.

These presidential initiatives entailed the formation of three task forces: the Disparities Task Force, Culture of Leadership Task Force, and Community Practitioner Leadership Task Force. These task forces were established early on in my presidency and have been actively working since then. We formed three subgroups within each task force that align with that respective task force's three goals, to ensure all goals have been adequately addressed. While all three task forces have issued final reports and recommendations for review and discussion at the Board meeting that will take place later this month during the 2022 AAAAI Annual Meeting in Phoenix, I would like to offer a progress report on what they have accomplished.

Disparities Task Force

The aims of the Disparities Task Force chaired by Carla M. Davis, MD, FAAAAI, are to identify, quantify, better understand the reasons for, and propose strategies to address disparities in three key areas:

- Outcomes for underserved minority patients with allergic and immunologic conditions.
- Discrepancies in the number of underserved minorities in medical school versus allergy and immunology fellowship training.
- Discrepancies in the number of underserved minorities in the field of allergy and immunology versus those in leadership positions in allergy and immunology.

To support these goals, the three subgroups of the Disparities Task Force have been:

- Engaging with the American Board of Allergy and Immunology (ABAI) to formally recommend a new content area in the ABAI Continuous Assessment Program (CAP) to address issues related to diversity, equity, and inclusion (DEI).
- Communicating with the AAAAI Research & Training Division and AAAAI Foundation to increase funding opportunities for research on health disparities and programs to provide funding for researchers from underrepresented minority (URM) backgrounds.
- Exploring outreach at medical schools to attract more URM candidates into our specialty.
- Gathering data from the Association of American Medical Colleges, Electronic Residency Application Service, and National Resident Matching Program to gain a benchmark of the current URM trainee pipeline to A/I fellowship programs in comparison to the general U.S. population.
- Updating processes to collect demographic information from members. This will allow AAAAI to clearly understand and accurately describe our membership and encourage diversity and inclusion.
- Discussing with the Community Practitioner Leadership and Culture of Leadership Task Forces to identify areas for improvement and inclusion, and develop recommendations for changes to the AAAAI Board recruitment and selection process.

Culture of Leadership Task Force

In addition to having processes in place for the mechanics of filling leadership positions, a concurrent, strategic and thoughtful process for equipping our future leaders with the tools for leadership success is needed. Because leadership training is not included in medical school, residency or allergy and immunology fellowship, it is critical we provide this training as part of AAAAI leadership development.

This was the rationale behind the Culture of Leadership Task Force, co-chaired by James T. Li, MD, PhD, FAAAAI, and myself, which focused on:

- Following the 2020-2023 AAAAI Strategic Plan to evaluate the metrics for success of the Leadership Institute, specifically the Leadership Course and Mentorship Program.
- Planning the target audience, topics, speakers, and format for the 2022 Leadership Forum.
- Assessing leadership development areas of need for our membership, and developing program content and delivery methods to meet those needs.

I am pleased to share that the progress made by the three subgroups of this task force includes:

- Launching a Leadership Forum to take place in September 2022 in Chicago targeted to meet the needs of established leaders in the AAAAI.
- Updating the Committee Chair Handbook. When someone assumes a new leadership position in the AAAAI, they can refer to this manual for a clear description of their roles and responsibilities, and policies and procedures for executing their committee work.
- Evaluating the Leadership Institute Course and Mentorship Program by establishing metrics of success to measure their impact.

Community Practitioner Leadership Task Force

Finally, the Community Practitioner Leadership Task Force co-chaired by Andrew W. Murphy, MD, FAAAAI, and Sharon B. Markovics, MD, FAAAAI, that aims to enhance and develop AAAAI leadership opportunities for community practitioners, has three specific goals:

- Review the nomination policies and procedures for the office of Secretary-Treasurer.
- Better understand, through focus groups/qualitative research, our community practitioners' perception of opportunities for them in leadership in the AAAAI.
- Increase leadership opportunities in the AAAAI for community practitioners.

To accomplish the above goals, this task force's three subgroups have done the following:

- Held listening tours with the RSL leadership and interest section leadership
- Sent a survey inquiring about possible obstacles to leadership in both the AAAAI and RSL structures. This survey went to the general membership of several of the RSLs with the help of the RSL Governors.
- Sent an additional survey to past AAAAI Board members and past Presidents asking about the AAAAI nominating process, and if changes were needed to increase community practitioner leadership opportunities.

If you would like to hear more about these presidential task forces, as well as leadership and how to get involved in the AAAAI, you can listen to episode 62 of the <u>AAAAI podcast series</u> that I recently recorded with David Stukus, MD, FAAAAI.

Thinking back to the first AAAAI Annual Meeting that I attended, I remember how excited and energized I was upon returning home. Considering our 2022 Annual Meeting in Phoenix will be the first time in nearly 3 years that we are able to gather again as a community, I anticipate feeling even more excitement and energy. Please remember that we have in-person and virtual attendance options for how **you** feel comfortable learning, and we have strong <u>Health</u> and <u>Safety Protocols</u> in place to keep those coming to Phoenix safe. In addition, attendees are able to change their registration from in-person to virtual-only, or vice versa, at any time at any time by logging into the <u>Annual Meeting registration site</u> and editing their existing registration. We have also added a <u>set of FAQs</u> with important information that I encourage you to read.

It has been an honor serving as AAAAI President, and it will be an honor to deliver my closing address at the Business Meeting and pass the gavel to David A. Khan, MD, FAAAAI, your next AAAAI President. If you will be in Phoenix, I hope to see you there.

Sincerely,

Hivelle Mosnain MD/NS FAAAAI

Giselle S. Mosnaim, MD, MS, FAAAAI AAAAI President president@aaaai.org

Claim your 2021 Virtual Annual Meeting Credits!



American Academy of Allergy Asthma & Immunology VIRTUAL ANNUAL MEETING FEBRUARY 26-MARCH 1, 2021

There is still time to claim your 2021 Virtual Annual Meeting Credits. Continuing education credits and

attendance certificates can be claimed online through **March 1, 2022**.



Claim credits now!

It's about time for a system built just for allergists

There's a new player in the allergy space.

Meet ModMed[®]'s comprehensive, allergy-specific system that helps automate many of the manual tasks that eat up your time.

From patient self-scheduling to an EHR system that documents as you go, you now have the tools to help you sail through your day.

ALLERGY-SPECIFIC EHR + PM + ANALYTICS + PATIENT ENGAGEMENT

						iPad 🗢	3:02 PM						_	* 39% 📼	
						Jane Doe	Arrived	Tasks		me Ask Watson	More C	Overview Histo	0	ی Drawing	₽ No e/m
	10:54 AM						THITTOU							, in the second se	
	Cancel		Allergy Testin	g/Mixing		Impressions Findings	Visual DX		Acrodermatiti	s Continua of Hallo	opeau			Drav	w Camera
		Allergy	Testing Panels Positive Allerger	Allergen Mixing 1	Tables				-	0 11 0	~		1	S	Special Plans
10:52 AM	Select Source of Mixing Tables		Date of Test Results		Tyg	Impressions	0		10		-	Morphologi	ies		Morph
Cancel Allers		ts +	N/A		SI	Sinusitis, acute		15	261	79	CALL OF THE OWNER	Total Body Surfa			Ddx
Allergy Testing Panels Pos	Mixing Table - Vial 1					Basal Cell Carcinoma		P	261				CE Alea (70)		Assoc. Dx
Group of Panels: General Allergens +	Allergen Name	Final Endpoint	Concentration (Dilution)	Volume		basat Cett Carcinonia	P	2		19	12 100	\bigcirc			Status
	Egg White	4	1 +	100.00 ml		Rhinitis, allergic		essions	DURIN		Talla	Psoriasis PGA		[New Dx
Panel A (Foods) 0/5 Panel B (Trees) 0/4	Comments		Total Diluent	Total Antigen Volume	Tot	Acute bronchiolitis		du	2						In The Life of
> Panel C (Grasses) 0/4						Acrodermatitis Continua	.6		NA.			Custom Morpho	logy		
> Panel D (Weeds) 0/5	Mixing Table - Vial 2					Hallopeau	or 🗸 -			(Interas	120 6	coalescent pust	ules with		Ears
> Panel E (Epithelials) 0/5	Allergen Name	Final Endpoint	Concentration (Dilution)	Volume		Bilateral hearing loss, Sensorineural				Sec. State	-	erythema and n skin inspect detail	ail dystrophy		00
> Panel F (Molds) 0/3	Cockroach	5		ml		Benign neoplasm thyroid				1	9	11			Mouth
Comments	Comments		Total Diluent	Total Antigen Volume	Tot	beingin neoptasin triyroid		>				201			
	-		m	ml	-	Deviated nasal septum			H /	N/C		B V			00
								201	A DECEMBER OF	and the second se		and the second second			Sagittal

Experience allergy software done right at AAAAI FEBRUARY 26-28 | BOOTH #1350 modmed.com/Allergy_AAAAI | 561.235.7506





An allergist / immunologist membership organization dedicated to advancing the knowledge and practice of allergy, asthma and immunology for optimal patient care.

What's New at aaaai.org

Spring Is Around the Corner – Check Your Local Pollen Counts

The AAAAI's National Allergy Bureau^m (NAB^m) is the most trusted resource for accurate pollen and mold levels for you and your patients. Be sure to <u>keep</u> <u>this URL</u> handy as the pollen levels rise to share with your patients.

Listen to New Conversations from the World of Allergy Podcast Episodes

AAAAI's podcast series offers episodes for both physicians and patients on a wide array of allergy/immunology topics. CME credit is available for some of the episodes. New episodes are added monthly, so <u>make sure to check back</u> <u>often</u>.

Featured CME Opportunities

Access 2021 Virtual Annual Meeting Content Before It Expires

Content from the 2021 AAAAI Virtual Annual Meeting is still available through March 1, 2022, giving you the opportunity to access over 100 hours of educational content. <u>Click here to learn more</u>.

Provide Optimal Care for PIDD Patients

"Providing Enhanced Medical Support for Patients with Primary Immunodeficiency Disorders (PIDD)" helps address knowledge gaps in PIDD. The program consists of four online modules that will provide you with information about best practices for diagnosing, treating and communicating with patients, and offers MOC part IV credit.

Targeted Education About Medicine for Schools (TEAMS) Anaphylaxis: The Allergist's Guide to Equipping Schools for Allergy Emergencies

This course was developed to teach allergy professionals how to apply allergy expertise to school-targeted allergy education. It will also explain how to navigate the multiple cultures and chains of command at schools and help learners understand legal issues and indemnification, allowing you to enjoy serving your community while minimizing anxieties of potential liability. Throughout the course, you will access content that will equip you to teach at your local K-12 schools.

Demystifying IgE-Mediated Cow's Milk Allergy: Diagnosis and Management: 2021 Update_

Diagnosis and management of cow's milk allergy can be challenging and impact quality of life. This <u>online module</u> is designed to help you diagnose and manage cow's milk allergy in your practice.

Oral Immunotherapy (OII) for Treatment of Food Allergy: 2021 Update

<u>This interactive course</u> provides information about the different types of food immunotherapy. Examine the current evidence supporting OIT's use, and the importance of shared decision making with patients and families to identify which patients might benefit most from this therapy.

Your Guide to the 2022 AAAAI Annual Meeting



American Academy of Allergy Asthma & Immunology ANNUAL MEETING PHOENIX, AZ · FEBRUARY 25–28, 2022 Welcome back to the AAAAI Annual Meeting! This year's live event will take place in Phoenix, and we're excited to be able to gather in person as a community again. While the Annual Meeting focuses on educational offerings for A/I professionals in practice and academia, an in-person event also provides you with the opportunity to connect with colleagues, attend social events and practice your skills.

This guide will provide important details for attendees, whether you'll be joining us in Phoenix or virtually. Make sure to also check <u>annualmeeting.aaaai.org</u> for the most up-to-date information.



Need to Know

Location

Sessions held as part of the 2022 AAAAI Annual Meeting will take place at the following locations:

Phoenix Convention Center

100 N. Third Street Phoenix, Arizona 85004

Sheraton Phoenix (Co-Headquarter Hotel) 340 N. Third Street Phoenix, Arizona 85004

Hyatt Regency Phoenix (Co-Headquarter Hotel) 122 N. Second Street Phoenix, Arizona 85004

Transportation

The Phoenix International Airport offers various types of ground transportation for your visit. Shuttles, rental cars, taxis, the Metro Light Rail and ride share services (such as Lyft and Uber) are all available.

Taxi service from the Phoenix Sky Harbor International Airport to the Phoenix Convention Center and nearby hotels is approximately 10-15 minutes and costs around \$20 to \$25, not including gratuity (traffic during peak times will cause delays and increased fares). Public transportation via the Metro Light Rail is approximately 20 minutes and \$2 one-way.

Member Resource Center

Phoenix Convention Center, North Building, Lower Level, Hall 6 Concourse Visit the AAAAI Member Resource Center to take advantage of Annual Meeting discounts on public education products, pay dues or update your membership information.

Member Resource Center Hours Thursday, February 24: 12:00 to 6:00 pm Friday, February 25: 7:30 am to 4:00 pm Saturday, February 26: 7:30 am to 4:00 pm Monday, February 27: 7:30 am to 2:00 pm

Exhibit Hall

Phoenix Convention Center, North Building, Lower Level, Hall 4

The exhibiting companies and organizations will provide you with the latest information on products and services in the field of allergy/immunology.

Exhibit Hours

Saturday, February 26: 9:45 am to 3:15 pm Sunday, February 27: 9:45 am to 3:15 pm Monday, February 28: 9:45 am to 2:00 pm

Journals Booth & Sessions

Phoenix Convention Center, North Building, Lower Level, Hall 6 Concourse Meet representatives from *The Journal of Allergy and Clinical Immunology* (JACI), the most-cited allergy/immunology journal, and sister journals *The Journal of Allergy and Clinical Immunology: In Practice* (JACI: *In Practice*) and *The Journal of Allergy and Clinical Immunology: Global* (JACI: *Global*).

JACI and JACI: *In Practice* will both have sessions at the 2022 AAAAI Annual Meeting.

JACI: *In Practice* Year in Review Friday, February 25 at 12:45 pm

This session will give an overview of the most up-to-date research in JACI: *In Practice*. Some of the most commonly managed clinical problems will be covered including asthma, food allergy, anaphylaxis, drug allergy and urticaria/angioedema. The editors will present a curated selection of papers from the 2021 issues of JACI: *In Practice*, first in a didactic manner, followed by a question and answer format with the participation of the audience.

JACI Year in Review Saturday, February 26 at 4:45 pm

This session will give an overview of the most up-to-date research in the JACI, covering key interest sections of chronic rhinosinusitis, pollution and allergy/immunology, and immune dysregulation, along with other related JACI content supporting these topics.

Capacity Limits

If you are attending in-person in Phoenix, try to get to sessions as promptly as possible. Due to the physical distancing between seats, there may be less capacity in meeting rooms than usual. Overflow rooms will be available for some sessions.



Registration Desk Location and Hours Phoenix Convention Center, North Building, Lower Level, Hall 6 Concourse

Registration Desk Hours

Thursday, February 24: 6:30 am to 7:00 pm Friday, February 25: 6:30 am to 5:00 pm Saturday, February 26: 6:30 am to 5:00 pm Sunday, February 27: 6:30 am to 5:00 pm Monday, February 28: 6:30 am to 4:00 pm



Need to Know: Virtual Attendees

Starting Friday, February 25 through Monday, February 28, some sessions will be live-streamed online in nearly every timeslot during the program. These include a variety of session types including plenaries, the keynote, symposia, workshops and oral abstract sessions.

The live-streamed sessions, as well as almost all other sessions presented in-person in Phoenix, will be recorded and made available online for playback within a week after the inperson meeting ends.

Starting Thursday, February 24, a library of 69 pre-recorded courses, symposia and workshops will be available online to all attendees, whether participating in-person or virtually.

All recorded content—both the prerecorded sessions and the recordings of sessions presented in-person—will be available for viewing through December 31, 2022. Attendees will have access to 290.25 hours of educational content in total.

Health and Safety Protocols

The AAAAI is committed to the health and safety of our members, staff and other attendees. We will continue to monitor the COVID-19 pandemic and follow all local, state and federal recommendations to ensure a safe, enjoyable and productive Annual Meeting.

For those individuals attending the 2022 Annual Meeting in Phoenix, these are our current Health and Safety Protocols. Health and Safety Protocols are subject to change at any time and will be <u>posted here</u>. <u>Read our FAQs here</u>.

- All attendees are required to be fully vaccinated and will be asked to show proof of vaccination when they pick up their registration badge. There are no exceptions to this.
- **Masks** will be required at all times in meeting rooms and common areas.
- **Social distancing** protocols of at least 3 feet will be honored.
- **Standing and/or congregating** in the back of meeting rooms is not allowed.
- Food distribution will follow CDC guidelines.
- **Spouses/guests** may attend AAAAI events after showing proof of vaccination when picking up their registration badge.
- International Attendees will need to show proof of full vaccination with one of the vaccines approved by the World Health Organization.

The clinical theme of the 2022 AAAAI Annual Meeting is Difficult to Control Asthma.

Plenary and Keynote Schedule Friday Presidential Plenary: Digital Health and Remote Patient Monitoring for Patients with Difficult to Control Asthma February 25 at 2:15 pm

Patients with difficult to control asthma may have low health literacy, poor inhaled controller medication adherence and technique, high exposure to indoor and outdoor environmental triggers, and reduced access to care. This session will address how digital health technologies and remote patient monitoring systems can address the above challenges, as well as their limitations.

Saturday Plenary: Preparing for the Next Pandemic: From Mechanisms to Vaccines February 26 at 8:15 am

The worldwide COVID-19 pandemic is the most devastating public health crisis since Spanish influenza in 1918. This session will impart learned strategies to prepare for future pandemics. It will highlight the federal response and how science is leveraged to identify underlying immune mechanisms and rapidly implement novel vaccine strategies.

Sunday Plenary: Anaphylaxis: Novel Mechanisms and Emerging Therapeutic Interventions

February 27 at 8:15 am

This session will describe novel discoveries in the field of mast cells, IgE and anaphylaxis. It will also cover novel therapeutic approaches to prevent anaphylaxis.

Monday Plenary: An Ounce of Prevention February 28 at 8:15 am

This session will include presentations from world-renowned experts regarding prevention of food allergy and other allergic diseases. The issue of prevention is of critical importance in the context of increasing prevalence of allergic diseases throughout the world.

Keynote: The Importance of Diversity in Academia and Team Performance

Saturday, February 26 at 3:30 pm

Hannah Valantine, MD, who has devoted much of her career to improving diversity and inclusion, will deliver the 2022 Keynote. She will present the evidence underlying the value and impact of diversity, equity, inclusion and justice in academia and in team performance. She will discuss innovative strategies for achieving a culture of inclusive excellence in academia, focusing on her work at the NIH.



Use Your Smartphone or Tablet at the 2022 AAAAI Annual Meeting

Here are a few reasons why you should make sure to pack your smartphone or tablet when you come to Phoenix:

The 2022 Annual Meeting app can be

used to interact with other attendees, organize your schedule, evaluate speakers and sessions, stay current with push notifications and navigate



the Phoenix Convention Center and Exhibit Hall with interactive maps. It's available on the App Store or Google Play for your smartphone or tablet. The app is supported in part by AstraZeneca.

Evaluations

to provide

CMF

feedback on Annual Meeting faculty and sessions will be available exclusively through the AAAAI Annual Meeting app.

Claim credit at the Annual Meeting

before you even exit the session. You can claim credits at

<u>annualmeeting.aaaai.org</u> or through the 2022 Annual Meeting app.

Post to Twitter and other social media channels using the official hashtag, #AAAAI22, or simply follow

along to see what other attendees are saying about the Annual Meeting.

Audience Response

Systems will be available in select sessions. Speakers may take questions, raise quick polls



or gather feedback over the Annual Meeting app to engage the audience in real time.

Looking for Handouts?

The most up-to-date versions of the 2022 Annual Meeting handouts are available to meeting delegates <u>on the Online Planner</u> during and after the Annual Meeting, and in the session listings in the mobile app. Delegates are able to view, download and print available session handouts. Handouts can be searched by session number, session title or a speaker's last name.

There is also a Handout Printing Station in the Phoenix Convention Center, North Building, 100 Level, 129A Concourse.

Don't Miss the Featured Poster Session and Reception Sunday, February 27 from 4:45 to 6:15 pm

The featured poster session and reception is your chance to learn more about the best of the best abstracts at the Annual Meeting. Only the top ranked abstracts are chosen to be part of this special session. Come learn more about the latest research in A/I and ask the authors questions about their work while enjoying light refreshments and drinks.

You can also join us for the COVID-19 Featured Poster Session on Saturday, February 26. These featured COVID-19 posters will be displayed all day Saturday, and authors will be present to answer questions from 12:00 to 1:00 pm.

Make Time for the Interest Section Forums

On Sunday, February 27 from 3:30 to 4:30 pm, Interest Section Forums will take place. These forums allow each interest section of the AAAAI to discuss business and provide education, making it a great time to investigate an interest section you may be interested in joining. Continuing education credits are available for these activities.

Earn CME at the AAAAI Annual Meeting

The 2022 AAAAI Annual Meeting will be a leading venue to expand your knowledge and skills in allergy/ immunology and will provide the opportunity to meet—and possibly exceed—the CME requirements needed for Maintenance of Certification (MOC).

If you attend the Annual Meeting in person, you can earn up to 41.25 *AMA PRA Category 1 Credits*[™]. By attending three consecutive days of the 2022 Annual Meeting, you can earn up to 25.00 CME credits, meeting the MOC Part II requirement of 25 CME credits per year.

All registrants will have access to a full range of virtual content. The combination of pre-recorded, in person, and recordings of in-person sessions will offer up to 290.25 hours of educational content, available for both CME and CE credit.

The American Academy of Allergy, Asthma & Immunology (AAAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AAAAI designates this live activity for a maximum of 290.25 AMA PRA Category 1 Credits[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Academy of Allergy, Asthma & Immunology is a Provider, approved by the California Board of Registered Nursing, Provider #10704, for up to 290.25 Contact Hours.

Supporting every area of your practice every day



2022 AAAAI Annual Meeting - Practice Management Hub

Phoenix Convention Center, North Building, Lower Level Concourse

Friday noon to 4:00 pm Saturday 8:00 am to 5:00 pm Sunday 8:30 am to 4:00 pm Monday 9:00 am to noon

Expert Office Hours

Friday February 25, 2022

1:30 – 2:15 pm - Managing Biologics/Buy and Bill *Priya Bansal, MD FAAAAI* Practice Management Committee, Chair

1:30 – 2:30 pm - Penicillin Allergy Testing Allison Ramsey, MD FAAAAI

3:00 – 4:00 pm - Telehealth Gary Steven, MD FAAAAI & Sakina Bajowala, MD FAAAAI

Saturday February 26, 2022

9:45 – 10:45 am - Navigating the Job Market Christina Ciaccio, MD FAAAAI Practice Management Committee, Vice Chair

10:00 – 11:00 am - Payer Relations Richard Honsinger, MD FAAAAI Office of Practice Management, Payer Relations

11:00 am – 12:00 pm - Scope of Practice Stuart Abramson, MD PhD AE-C FAAAAI Advocacy Committee, Vice Chair

12:00 – 1:00 pm - Regional, State, & Local Allergy, Asthma & Immunology Societies (RSLAAIS) Weily Soong, MD FAAAAI RSLAAAIS, Chair 1:00 – 2:00 pm - AAAAI Practice Management Resources James Sussman, DO FAAAAI Office of Practice Management, Chair

3:00 – 4:00 pm - The AAAAI Registry Gary Steven, MD FAAAAI The AAAAI Registry, Medical Director

Sunday February 27, 2022

9:30 – 11:00 am - Compounding *Emily L. Graham, RHIA CCS-PVP* Hart Health Strategies, Inc.

11:00 am – 12:00 pm - AMA Delegates Steven G. Tolber, MD FAAAAI, Lynda Kabbash, MD FAAAAI, & Shahab Virani, MD

2:00 - 3:00 pm - Advocacy

Paul Williams, MD FAAAAI Advocacy Committee, Chair Emily Graham, RHIA CCS-PVP Hart Health Strategies, Inc.

2:30 – 3:30 pm - Mobile health technologies Sunit Jariwala, MD FAAAAI Health Informatics, Technology and Education Committee, Chair

Because Practice Matters! to the AAAAI

HELP SUPPORT A/I RESEARCH

Your 2022 gifts to the GAIN Campaign will support research in 2023!



Donate today at **aaaaifoundation.org/give**



Funding research that leads to the prevention and cure of asthma and allergic and immunologic disease

Proudly sponsored by



Join Us for These Social Events at the 2022 Annual Meeting

The AAAAI Foundation is eager to welcome you back to a live Benefit and 5K Run/Walk during the upcoming AAAAI Annual Meeting. These events provide you the opportunity to support A/I focused research with your friends and colleagues in a more relaxed setting.



We look forward to seeing you at the upcoming AAAAI Foundation Annual Benefit on Saturday, February 26 from 7:00 to 10:00 pm at the Hyatt Regency Phoenix. This is the premier social event of the AAAAI Foundation and includes the presentation of the 2022 Faculty Development Awards. A seated dinner featuring a plated duet entrée will be served, and no nuts, pork or shellfish will be on the menu.

Cocktail attire is appropriate.

Ticket Prices	
Patron Table of 10:	\$3,000
Patron Individual Ticket:	\$300
NAIA & Allied Health Individual Ticket:	\$200
Student Individual Ticket:	\$125

Seating for this event is limited. Click here to get more information.

This event is sponsored by Genentech.



2022 AAAAI Foundation Annual 5KRun/Walk

Registration is open for the 10th Annual AAAAI Foundation Annual 5K Run/ Walk, taking place in downtown Phoenix, on February 27. The route will travel through downtown Phoenix and take you past the Arizona Capitol Building and Wesley Bolin Memorial Plaza.

Feeling competitive? Awards will be presented for the following categories:

- Fastest Individuals Men's and Women's
- Fastest Team
- Most Fundraised

Event Timeline

On-site Music and Registration: 4:30 - 5:15 pm **Group Warm-Up:** 5:15 pm **Race Start:** 5:30 pm

Event Location

W. Washington Street between N. 7th Ave and 8th Ave

Registration is \$45 prior to the Annual Meeting or \$50 if you register onsite.

This event is sponsored by Takeda.



Better Health, Brighter Future



IS IT SYSTEMIC MASTOCYTOSIS?

Best Practices for Diagnosis and Management



REGISTRATION AT 6:15 AM

SHERATON PHOENIX DOWNTOWN Phoenix Ballroom A (3rd Level)





TRACY I. GEORGE, MD

University of Utah School of Medicine Salt Lake City, Utah



MATTHEW J. HAMILTON, MD Harvard Medical School

Harvard Medical School Boston, Massachusetts



ANNE MAITLAND, MD, PHD Mount Sinai South Nassau

Oceanside, New York



LAWRENCE B. SCHWARTZ, MD. PHD

Virginia Commonwealth University Richmond, Virginia

Americans With Disabilities Act

& Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact us prior to the live event at info@exchangecme.com.



REGISTER TODAY Exchange**CME**.com/2022SMPhoenix

TARGET AUDIENCE

Allergists/clinical immunologists, dermatologists, gastroenterologists, hematologists/oncologists, and other specialist clinicians who treat patients with nonadvanced systemic mastocytosis.

EDUCATIONAL OBJECTIVES

- Describe clinically relevant pathophysiology in the development of systemic mastocytosis, including the effects of driver mutations on mast cell hyperactivation
- Identify patients with nonadvanced systemic mastocytosis based on symptomology and appropriate ancillary testing
- Discuss the clinical profiles and trial evidence for current and emerging targeted treatment options in nonadvanced systemic mastocytosis
- Tailor therapeutic regimens for patients with nonadvanced systemic mastocytosis based on symptoms, risk stratification, treatment responses, and appropriate consultations with other specialist clinicians



T M S 🞯

This activity is provided by Integritas Communications.

This activity is supported by an independent educational grant from Blueprint Medicines Corporation.

This activity is endorsed by The Mast Cell Disease Society, Inc.

This live activity will not offer continuing medical education credit.

This program is not sponsored or programmed by the AAAAI.

There is no registration fee for attending this program, however, seating is limited. Preregistration does not guarantee seating. We recommend arriving at the symposium location early.



Explore Phoenix During the 2022 AAAAI Annual Meeting

When you're not attending sessions or AAAAI social events, take the time to explore the city of Phoenix. This world-class destination has a bustling downtown and enough attractions and hiking trails to keep you busy for days.

Phoenix offers something for everyone, and we've put together some recommendations of activities to do while you're in the area.

Musical Instrument Museum

This museum displays thousands of instruments from all across the world. The gallery spaces allow you to see a variety of instruments, and the hands-on Experience Gallery is where you can try out different instruments. You will also find a section of the museum displaying instruments played by famous artists. Event space within the museum hosts concerts, so make sure to check out their event schedule.

Desert Botanical Garden

Get a closer look at more than 50,000 arid plants from across the globe in this 140 acre outdoor garden. You will follow a series of themed trails that will teach you about desert plant life and the garden's conservation efforts. Once you've finished wandering the trails, you can shop in their store or get a meal at one of their onsite restaurants.

Japanese Friendship Garden

The Japanese Friendship Garden is a joint project between the city of Phoenix and their sister city of Himeji, Japan. The 3.5 acre garden features serene walking paths, which will take you past flowing streams, a waterfall and 50 plant varieties. The garden also hosts workshops, classes and events, which allow visitors to learn more about Japanese culture.

Wrigley Mansion

This mansion was designed by chewing gum magnate William Wrigley Jr. as a gift for his wife. It sits atop a hill, allowing for gorgeous views of Phoenix and the surrounding mountains. It has been transformed into an event and fine-dining venue, which provides you with a beautiful location for dining while in Phoenix. You can also join a tour which covers the history of the mansion.

Heard Museum

Internationally recognized for its collections and exhibits, the Heard Museum is one of the best ways you can learn about the culture and art of indigenous people. The museum works directly with artists and native tribes to display both traditional and contemporary art to visitors. A visit to the museum will teach you more about indigenous people's experiences through the lens of their art.

Goldfield Ghost Town

While this attraction is just outside of Phoenix, it offers a rare opportunity to explore what life was like during the gold rush. Join a guided tour to explore the old mine, explore the museum, which gives more details on the history of the town, and shop from the many vendors. This is a great activity for kids if you will be bringing the entire family with you to Phoenix.

Go Hiking

The American Southwest is famous for its National Parks and rock formations, and you don't need to travel far to get some amazing hikes in. There are hikes available for all skill levels within a short drive of the greater Phoenix area. Some of the most popular include the trails in Papago Park, the Phoenix Mountains Preserve and Pinnacle Peak Park.

Pueblo Grande Museum and Cultural Park

This archaeological site was once inhabited by the Hohokam culture and is a National Historic Landmark. It is the largest preserved archaeological site in Phoenix. A short trail will lead you through the archaeological site, allowing you to view ruins and reconstructed buildings. The museum portion contains three galleries that showcase artifacts, plus a hands-on area for children.



AAAAI Officially Launches New Gold Open Access Journal

The Journal of Allergy and Clinical Immunology: Global (JACI: Global), the AAAAI's new Gold Open Access Journal, officially launches Tuesday, February 15.

"We are very excited to introduce JACI: *Global* to the A/I community at this year's Annual Meeting," said David B. Peden, MD, MS, FAAAAI, Editor-in-Chief of the new publication. "JACI: *Global* provides a home for research that is in early stages of development and may provide a good rationale for larger studies. There are a lot of good, early stage studies out there, that may be small sample size or just not ready for prime time and they didn't have a home. Now they do."

The new journal began accepting submissions in September 2021 and <u>published several studies online</u> ahead of the official launch of the first edition earlier this month.

JACI: *Global* provides authors the opportunity to publish in a journal that will reach the global community, with no barrier to access for anyone with an internet connection. "Global really has two meanings," Dr. Peden said during a recent episode of <u>Conversations</u> from the World of Allergy, the AAAAI's podcast. "One is that we are reaching out to be more embracing to global authors. Global also means we are providing a more global expanse of the practice of science." True to its name, JACI: *Global* has received submissions

from countries in Africa, Asia, Australia, New Zealand, Europe, North America and South America.

JACI: *Global* joins the AAAAI's distinguished family of journals, JACI, the most cited journal in the field of allergy and clinical immunology, and JACI: *In Practice*, which places an emphasis on practical clinical research and the latest recommendations for diagnosis and treatment.



Lanny J. Rosenwasser, MD, FAAAAI, at the University of Colorado Denver School of Medicine in Aurora, Colorado, and Mimi L. K. Tang, PhD, MBBS, FRAC, FRCPA, FAAAAI, at Murdoch Children's Research Institute in Parkville, Australia, have joined the JACI: *Global* team as associate editors.

Visit the Journals booth at the AAAAI Annual Meeting to learn more about JACI: *Global* and pick up complimentary copies of <u>JACI</u> and <u>JACI</u>: *In Practice*.

Get your 2022 AAAAI Annual Meeting Program with the tap of a finger!

Download the 2022 AAAAI Annual Meeting app from the App Store or Play Store on your mobile device.

- Easily locate session handouts, abstracts and evaluations, (Note: This will be the ONLY place to access session evaluations.)
- Research speakers and add their sessions to your calendar.
- Learn about last minute program changes.
- Navigate with interactive maps.
- Interact with other members through the app.



Supported in part by

AstraZeneca



Get Mentored Career Advice at the Faculty Development Program



The 2022 program will be a live event in Milwaukee, Wisconsin

Meet with A/I mentors, connect with colleagues and get feedback on your research projects during the 2022 AAAAI Faculty Development Program. This program is designed specifically to help you build your network and receive individual mentorship from experts in the field.

The AAAAI is thrilled to offer the Faculty Development Program in person again, this time September 22-25, 2022, in the vibrant city of Milwaukee. Meet face-to-face with mentors who will give you personalized advice about your research, career goals, grant writing and work-life balance. You'll also have the opportunity to present your research to discuss its implications with individuals from a wide range of backgrounds who may offer insights that haven't occurred to you yet.

To foster connections in a more relaxed setting, social events are built into the schedule to allow you to enjoy the city of Milwaukee while you get to know your colleagues. These connections will continue to benefit you throughout your career.

We want you to have the opportunity to access this important professional development opportunity, which is why this program is fully funded for all accepted applicants, including airfare.



"I was blown away by how much quality advice the mentors gave to me after only a few short minutes of knowing me. This outside perspective was what I really needed to re-evaluate my career trajectory."

— Melanie C. Dispenza, MD, PhD, Johns Hopkins University School of Medicine



Eligibility Requirements:

- Senior fellow-in-training or junior faculty, as defined below. Senior fellow-in-training: an individual who has completed at least one year of training in allergy/immunology and will still hold a training position at the time of the program. Junior faculty: an individual who has graduated from a clinical allergy/immunology training program within the previous four years (2018 or later) and holds a faculty position in a U.S. or Canadian institution.
- 2. Based at an accredited institution in the United States or Canada.
- 3. Committed to attending the full duration of the program, September 22-25, 2022.
- 4. Must be a member of the AAAAI.

Program space is limited to ensure all participants have the time to connect closely with mentors and other colleagues. The application site will open March 7. Learn more and get ready to apply.



Clinical Perspectives on an Oral Prophylactic Therapy for HAE: A Case-Based Approach



Capsule not actual size

Monday, February 28, 2022 | 6:30 ам – 7:30 ам МТ Buffet breakfast will be offered.

Register at www.oralhaetherapy.com!

For US healthcare professionals only. This program does not offer continuing education (CE) credits.

Join us for a dynamic and interactive discussion where we will explore an oral therapy option in HAE, including its safety and efficacy data, as the expert faculty presents patient case profiles. Learn how to initiate therapy for this oral prophylactic therapy that can help reduce HAE attack rates for your patients. The presentation will be followed by a live Q&A session with the faculty. An HAE program not to be missed!

OBJECTIVES

- Define hereditary angioedema (HAE), describe its substantial clinical impact, and review how it is diagnosed
- Explore the burden of treatment for patients with HAE and the demand for an oral prophylactic therapy
- Describe the clinical profile of ORLADEYO[®] (berotralstat), the first and only targeted oral prophylactic therapy for HAE
- Review how to initiate therapy with ORLADEYO in your patients

LOCATION

Sheraton Phoenix Downtown 340 North Third Street, Phoenix, AZ Meeting Room: **Phoenix Ballroom D, Third Level**

SPEAKER



Michael E. Manning, MD Clinical Assistant Professor, Internal Medicine, UA College of Medicine-Phoenix President/Medical Director, Allergy, Asthma & Immunology Associates, Ltd. Scottsdale, AZ

You can also visit us at **exhibit booth #223** to learn more about ORLADEYO and chat live with a representative.

INDICATION

ORLADEYO® (berotralstat) is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.

Limitations of use

The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for the treatment of acute HAE attacks. Additional doses or dosages of ORLADEYO higher than 150 mg once daily are not recommended due to the potential for QT prolongation.

IMPORTANT SAFETY INFORMATION

An increase in QT prolongation was observed at dosages higher than the recommended 150 mg once-daily dosage and was concentration dependent.

The most common adverse reactions (≥10% and higher than placebo) in patients receiving ORLADEYO were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease.

A reduced dosage of 110 mg taken orally once daily with food is recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) and in patients taking chronically administered P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) inhibitors (eg, cyclosporine).

Berotralstat is a substrate of P-gp and BCRP. P-gp inducers (eg, rifampin, St. John's wort) may decrease berotralstat plasma concentration, leading

to reduced efficacy of ORLADEYO. The use of P-gp inducers is not recommended with ORLADEYO.

ORLADEYO at a dose of 150 mg is a moderate inhibitor of CYP2D6 and CYP3A4. For concomitant medications with a narrow therapeutic index that are predominantly metabolized by CYP2D6 or CYP3A4, appropriate monitoring and dose titration is recommended. ORLADEYO at a dose of 300 mg is a P-gp inhibitor. Appropriate monitoring and dose titration is recommended for P-gp substrates (eg, digoxin) when coadministering with ORLADEYO.

The safety and effectiveness of ORLADEYO in pediatric patients <12 years of age have not been established.

There are insufficient data available to inform drug-related risks with ORLADEYO use in pregnancy. There are no data on the presence of berotralstat in human milk, its effects on the breastfed infant, or its effects on milk production.

To report SUSPECTED ADVERSE REACTIONS, contact BioCryst Pharmaceuticals, Inc. at 1-833-633-2279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here to see the <u>full Prescribing Information</u> for ORLADEYO.

For Colorado prescribers, please see information regarding the <u>Wholesale Acquisition Cost</u>.

For Vermont prescribers, please see information regarding the <u>Average Wholesale Price</u>.



BioCryst and ORLADEYO are registered trademarks of BioCryst Pharmaceuticals, Inc. © 2022 BioCryst Pharmaceuticals, Inc. All rights reserved. US.ORL.00683 1/22



What the Interest Sections Are Doing for AAAAI Members

Introducing the Interest Section Corner

Welcome to the first Interest Section Corner, a new column that will appear in issues of *Impact*! We look forward to introducing you to the AAAAI interest sections: Anaphylaxis, Dermatology and Drug Allergy (ADDA), Asthma Diagnosis and Treatment (ADT), Basic and Clinical Immunology (BCI), Environmental and Occupational Respiratory Diseases (EORD), Food Allergy and Eosinophilic Disorders (FAED), Health Outcomes, Education, Delivery and Quality (HEDQ), Immunotherapy, Rhinitis, Sinusitis and Ocular Diseases (IRSO), and Mechanisms of Asthma and Allergic Inflammation (MAAI). In each edition of *Impact*, we will highlight two interest sections and their exciting work.

Basic and Clinical Immunology (BCI):

I'm Rebecca Scherzer, MD, FAAAAI, and as the Chair of the BCI Interest Section, I'd like to tell you a little bit about BCI and its associated committees and how you can benefit from joining us.



• The goal of the BCI Interest Section is to allow for collaboration between those who have an interest in clinical and basic science

topics, including primary and secondary immunodeficiency disorders, autoimmunity, immune dysregulation, autoinflammatory disorders and vaccines.

- Members of our interest section include clinicians and researchers working to improve care for a diverse group of patients with diagnoses ranging from disorders of innate immunity to altered immune responses.
- There are four committees within BCI: Autoimmunity and Altered Immune Response; Genetics, Molecular Biology, and Epidemiology; Primary Immunodeficiency Diseases; and Vaccines.

Working with other members of BCI can provide guidance and mentorship for those who share common goals in their career paths. An example of how our interest section members share critical information with others are the practice suggestions in the guidelines created on how to care for patients with inborn errors in immunity during the current COVID-19 pandemic. The guidance was written by a group of BCI members and shared with the larger AAAAI community. BCI committees have recently updated educational slides on immunomodulation, and BCI members are actively collaborating with members of other interest sections to create an innovative education tool on the use of biologics for a variety of allergic and immunologic diseases that will be available to all AAAAI members. The members of BCI are also involved in writing work group reports that will be of great use to AAAAI members who treat patients with immunodeficiency disorders. Examples of these include the Secondary Hypogammaglobulinemia Work Group Report and the Biologics for PIDD Work Group Report.

Joining an AAAAI interest section provides the unique opportunity to work with others who have similar clinical and research interests to advance the knowledge and understanding of different diseases within our field. Interest sections are also an effective way to find collaborators and mentors. <u>Click here</u> for more information on AAAAI interest sections and the various interest section committees. You can also learn more by listening to <u>episode 49</u> of the AAAAI podcast series.

Joining an interest section is as simple as visiting your AAAAI member profile and selecting your primary interest section membership under the tab labeled *Involvement*.

Each interest section has a business meeting at the 2022 AAAAI Annual Meeting in Phoenix on Sunday, February 27 from 3:30 to 4:30 pm. Please check the 2022 AAAAI Annual Meeting <u>Online Planner</u> for the specific locations where each interest section is meeting. These business meetings are a great way to learn more about the different interest sections and meet other AAAAI members with similar clinical and research interests.

In addition to written materials, BCI members assist with planning AAAAI Annual Meeting sessions with the goal of sharing necessary information on timely topics in basic and clinical immunology. Members of BCI developed a successful interactive trivia session that debuted at the 2021 AAAAI Virtual Annual Meeting and we are using this innovative format again this year for a session on JAK-STAT pathways and JAK inhibitors. In addition to providing outstanding education, the BCI events at the Annual Meeting are a gathering place for clinicians and researchers looking to find collaborators and mentors who are interested in basic and clinical immunology.



Health Outcomes, Education, Delivery and Quality (HEDQ):

I am Princess U. Ogbogu, MD, FAAAAI, the Chair of the HEDQ Interest Section. The HEDQ Interest Section provides a forum for AAAAI members interested in promoting:

- Diversity, inclusion and equity in medical education and patient care
- Advancing digital health and technology for allergic and immunologic disease
- Encouraging quality and practice improvement
- Optimizing healthcare delivery

Our members are involved in clinical practice and in research focusing on health services, clinical informatics and health disparities. There are three committees within HEDQ: the Committee on the Underserved; the Health, Information, Technology and Education Committee; and the Quality, Adherence and Outcomes Committee. We have many active projects within these committees. Some highlights from 2021 include the publication of work group reports, podcast development, Annual Meeting sessions and advocacy initiatives.

• Members from our Committee on the Underserved have worked with the AAAAI Advocacy Committee, the AAAAI Presidential Diversity Task Force and the AAAAI journals to advance equity-related legislation, initiatives and policies, particularly those important to underserved patient populations and to improve diversity of healthcare professionals in A/I. Many of our committee members serve as reviewers for the AAAAI journals and editors of themed issues related to health equity and health disparities in A/I. In fact, with the help of the Committee on the Underserved, JACI: *In Practice* launched a new Case Studies in Health Disparities series in 2021.

- The Health, Information, Technology and Education Committee is active in the study and use of digital technologies in A/I and in promoting innovation in medical and patient education. Members create summaries of recent mHealth related articles for the JACI and JACI: *In Practice* and serve as a resource for AAAAI members in validating and developing mHealth applications. We also have presented Annual Meeting sessions and developed workgroup reports for artificial intelligence in A/I. Our members are very active in developing online resources, Annual Meeting sessions and publications focusing on medical and patient education as well as physician wellness initiatives.
- Our Quality, Adherence and Outcomes Committee promotes AAAAI initiatives for practice improvement, the AAAAI registry and our Choosing Wisely sessions for the AAAAI.

We encourage interested AAAAI members to select interest sections and join committees based on their professional goals.



American Academy of Allergy Asthma & Immunology

Keep up to date on the go... because Practice Matters!

Introducing a new AAAAI e-newsletter for the busy practicing allergist.

Visit **aaaai.org/practicescoops** to learn more and subscribe.

AAAAI-0222-182





Discover AYVAKIT® (avapritinib) at the 2022 AAAAI Annual Meeting

VISIT US AT BOOTH 458

LEARN MORE AT AYVAKIT.COM/HCP



AYVAKIT, Blueprint Medicines and associated logos are trademarks of Blueprint Medicines Corporation. © 2022 Blueprint Medicines Corporation. 02/2022 USBP-PRAVAASM-21.118.1

Insights from Young Investigator Caroline L. Sokol, MD, PhD, FAAAAI

Dr. Sokol is an allergist/immunologist and physician-scientist at Massachusetts General Hospital, and an Assistant Professor of Medicine and member of the Immunology Graduate Program at Harvard Medical School. She spends about 80% of her time running a laboratory, about 10% doing clinical work and the last 10% mentoring physician-scientist trainees. She received the AAAAI Foundation Faculty Development Award in 2019.

We're pleased to share an update on her research and work with the AAAAI.

On Her Research

My laboratory focuses on how the neuroimmune interactions drive the allergic immune response. We found that allergens are directly detected by sensory neurons, leading to itch responses and the release of neuropeptides that activate the allergic immune response. Not only is this a major paradigm shift for how we think about the initiation of allergic immune responses and itch, but it also tells us clinically that the skin is a hot spot for allergen detection—thereby linking atopic dermatitis and things like food allergy mechanistically as well as clinically.

On the AAAAI

I truly believe that clinical medicine only flourishes when it is supported by top-notch basic science. Because of this, I am dedicated to working within the AAAAI to promote basic science and especially to promote interactions between basic scientists and clinicians at the Annual Meeting to promote fertile crosstalk. I have just finished my term as Chair of the Cells and Mediators of Allergic Inflammation Committee, and hope to play educational and programming roles going forward.

Advice on Applying for the Faculty Development Award

Apply! And if you don't get it the first time (I didn't)-try again!

For more information on Dr. Sokol and our other grant awardees, please visit <u>aaaaifoundation.org</u>.

Don't Miss These Upcoming Sponsored Webinars

The AAAAI now offers non-CME webinars programmed by industry. The webinars may be pre-recorded or live events and will cover a variety of allergy/immunology topics.

You can find the <u>full updated listing by</u> <u>clicking here</u>.

Upcoming Sponsored Webinars

Expert Perspectives on Managing Moderate-to-Severe Atopic Dermatitis in Pediatric and Adult Patients Thursday, March 10, 2022

8:00 – 9:00 pm ET

This activity is provided by Med Learning Group, co-provided by Ultimate Medical Academy/Complete Conference Management (CCM) and supported by an education grant from Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. **The Future of Food Allergy: Novel Treatment Options on the Horizon** Wednesday, April 27, 2022 7:00 – 8:00 pm ET

This activity is supported by an educational grant from Genentech, a member of the Roche Group and provided by Physicians' Education Resource.



Meet the New Members of the AAAAI Board of Directors

The AAAAI Nominating Committee is pleased to announce the following candidates have been elected to the Board of Directors. The Secretary-Treasurer ascends to serve as AAAAI President, and the At-Large Directors serve 4-year terms. Their terms will begin at the Business Meeting that will take place during the 2022 AAAAI Annual Meeting in Phoenix.

Please join the AAAAI in congratulating them!

Thank you to every eligible voting member who participated in the 2022 Board of Directors election. Your votes have helped shape the future of the AAAAI and the specialty.



2022-2023 Secretary-Treasurer Paul V. Williams, MD, FAAAAI

Paul V. Williams, MD, FAAAAI, received his medical degree from the University of Washington, completed pediatric residency at the University of Rochester, and practiced

VOTE

general pediatrics for 10 years before entering an allergy fellowship at the University of Washington in 1988, completing it in 1991. Since that time, he has been a practicing allergist for Northwest Asthma & Allergy Center in the Seattle area until his retirement from active clinical practice in July of 2021. He is currently volunteering as an asthma specialist in a local free clinic. Although working full-time as an allergist, he also worked as curriculum coordinator for the Allergy Fellowship Program at the University of Washington for several years and was the Pediatric Resident Allergy Elective supervisor for the university until his retirement. He was a sub-investigator and lead investigator for industry-funded clinical research studies and served as the lead investigator for the Seattle center for the NHLBI-funded Childhood Asthma Management Program. Outside activities include former District Administrator for Little League Baseball, and elected Fire Commissioner.



2022-2026 At-Large Director Cem Akin, MD, PhD, FAAAAI

Cem Akin, MD, PhD, FAAAAI, is a clinicianscientist and a Professor of Medicine at the University of Michigan, Division of Allergy and Immunology. He obtained his internal

medicine training and PhD in microbiology and immunology from the University of Louisville, and completed his fellowship at NIAID/NIH in allergy and clinical immunology. He is recognized for his work on mast cell disorders, including mastocytosis, mast cell activation syndromes and anaphylaxis. As an Associate Professor at Harvard Medical School, he established the first multidisciplinary mastocytosis center at Brigham and Women's Hospital. He is currently leading clinical trials on tyrosine kinase inhibitors in indolent systemic mastocytosis. He has a long history of service to AAAAI, including Chair of the Grant Review Committee, and Chair of the Mechanisms of Asthma and Allergic Inflammation Interest Section. He has served on the Editorial Boards of JACI and Blood, and has written many original and review articles and book chapters for influential titles, including Harrison's and Cecil's Textbooks of Medicine and UptoDate. He is the past President of the Michigan Allergy Society, and currently enjoys teaching fellows, conducting clinical research and seeing a diverse population of allergy patients at the University of Michigan.





2022-2026 At-Large Director Priva J. Bansal, MD, FAAAAI

Priya J. Bansal, MD, FAAAAI, completed a 6-year BS/MD program and obtained her MD from University of Illinois-Chicago (UIC). She was Chief Resident in Internal Medicine/

Pediatrics at UIC and finished her allergy/immunology fellowship at Rush University Medical Center. She then worked in private practice and started her own private practice in 2019. She is Past President of the Illinois Society of Allergy, Asthma and Immunology. For the AAAAI, she was RSLAAIS Governor from 2014-2017. She also served as Chair of the Health Informatics, Technology & Education Committee. Since 2014, she has selected and edited the official Annual Meeting tweets. She served on the Communications Task Force and is the current Chair of the Communications Oversight Task Force. She is also Chair of the Practice Management Committee and Practice Management Workshop Planning Committee, and actively serves on the AAAAI COVID-19 Response Task Force. She has been a mentor of the Leadership Institute since 2018. She co-authored the AAAAI Telemedicine Work Group Report and a resource for COVID-19 and physician wellness. She is also on the AAAAI Disparities Task Force Health Outcomes Subcommittee.



2022-2026 At-Large Director Anna H. Nowak-Wegrzyn, MD, PhD, FAAAAI

Anna Nowak-Wegrzyn, MD, PhD, FAAAAI, is a Professor of Pediatrics at NYU Grossman School of Medicine, and the Director of the

Pediatric Allergy and Immunology Division, Department of Pediatrics, at Hassenfeld Children's Hospital in New York City. Her research interests focus on egg and milk allergies, baked milk and egg diets, food-induced anaphylaxis, novel diagnostics and immunotherapeutics for food allergy, oral tolerance development, and food protein-induced enterocolitis syndrome (FPIES). She served as the Chair of the Adverse Reactions to Foods Committee from 2013-2015 and as the Chair of the Food Allergy & Eosinophilic Disorders (FAED) Interest Section from 2019-2021. She is currently the FAED representative to the Practice, Diagnostics and Therapeutics Committee and a member of the Leadership Institute Executive Committee. She chairs the International FPIES Association Medical Advisory Board and led the AAAAI work group that wrote the first 2017 International Consensus Guidelines for the Diagnosis and Management of FPIES. She currently serves on the Executive Committee of the American Board of Allergy and Immunology and as the Deputy Editor for the Annals of Allergy, Asthma and Immunology.

Register to join us in-person or virtually: VindicoCME022522.eventbrite.com

CHRONIC SPONTANEOUS URTICARIA: How Will Emerging **Therapies Impact Treatment Paradigms?**

Friday, February 25, 2022

Sheraton Phoenix Downtown Phoenix Ballroom D, Third Level 340 North 3rd Street | Phoenix, AZ

6:30 - 7:00 PM MT In-person Registration and Dinner 7:00 - 8:30 PM MT **Educational Program**

Activity Chair Allen P. Kaplan, MD

Faculty Laura K. Ferris, MD, PhD Marc A. Riedl, MD, MS Kristin Sokol, MD, MS, MPH



Register to join us in-person or virtually: VindicoCME022522.eventbrite.com

> This program is not sponsored or programmed by the AAAAI.

This non-CME educational program is provided by



This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.





AAAAI members can save up to 25% on UpToDate[®]



Access current, comprehensive clinical content.

With **UpToDate**, you can easily access more than 10,500 evidence-based, practice-oriented topics across 24 specialties, making it one of the most relied on medical resources available.

More than 6,300 physician-authors draw from the latest evidence presented in over 470 medical journals, online medical resources and reports by major national and international agencies to provide information you can trust. As an American Academy of Allergy, Asthma & Immunology member, you can save up to 25% on an annual UpToDate subscription!*

Visit the American Academy of Allergy, Asthma and Immunology website (http://aaaai.execinc.com/edibo/UpToDate) and login to your member account. When logged in, you will be redirected to a private landing page on the AAAAI website with the UpToDate offer and a link to subscribe.

^{*}Savings on annual and longer subscriptions only and based on subscription type (quoted savings includes waived processing fee on new subscriber orders). AAAAI member prices are reflected in the UpToDate storefront when you are signed in to the AAAAI website with your membership login. Proof of trainee status is required for all trainee orders. Applicable taxes may apply.

IN BRIEF

In Memory: John A. Anderson, MD, FAAAAI



John A. Anderson, MD, FAAAAI, went to medical school in Chicago, Illinois before joining the U.S. Navy in 1962. He received his allergy/immunology training at Children's Hospital in Washington, DC, before going to Henry Ford Hospital in Detroit, Michigan in 1969, where he became head of the Division of Clinical Research and Chairman of Pediatrics.

He practiced there for 30 years. While the head of the division, he ran the Allergy Training Program.

During his career, he authored a number of publications and books and was a mentor to many. He served as AAAAI President in 1990, during which time he assisted in the development of the Education and Research Trust (which is now the AAAAI Foundation).

After leaving Henry Ford Hospital, Dr. Anderson continued to practice A/I in the private sector in Colorado and Arizona until he retired at age 80.

In Memory: Philip Fireman, MD, FAAAAI



Philip Fireman, MD, FAAAAI, completed his allergy/immunology fellowship at Harvard University and was a well-known expert in the characteristics of immunoglobulin. He was a Naval officer, a researcher and clinical fellow at the National Institutes of Health - Allergy, Immunology, and Infectious Diseases and later a Professor of Medicine and Pediatrics at the

University of Pittsburgh School of Medicine.

Dr. Fireman discovered a rare immune deficiency syndrome early in his career. He earned many honors and distinctions and contributed to over 200 publications, including his book *Atlas of Allergy*.

In addition to serving as President of the AAAAI in 1996, Dr. Fireman also served as Chairman of the American Board of Allergy and Immunology, and was a member of the American Board of Pediatrics and American Board of Medical Specialties. In honor of his memory, his family has requested that donations can be made in his name to the <u>AAAAI Foundation</u>.

Juanita Mora, MD, Named Practice Champion of the Year



The winner of the Regional, State and Local Allergy, Asthma & Immunology Societies (RSLAAIS) Practice Champion of the Year Award is Juanita Mora, MD, of the Chicago Allergy Center.

The award was presented in recognition of her community service and care for patients with

respect to housing, nutrition, employment and safety as well as her initiatives to educate and facilitate allergy treatment for patients in the community.

James T. Li, MD, PhD, FAAAAI, Presented with President's Award



The President's Award has been presented to James T. Li, MD, PhD, FAAAAI, in recognition of his commitment to leadership development within the AAAAI, which has left an immeasurable positive impact on the organization and on the field of allergy/ immunology.

Dr. Li is a Professor of Medicine at the Mayo Clinic and a Past President of the AAAAI.

ADDRESSING BARRIERS TO EOE DIAGNOSIS AND TREATMENT:

The Role of Updated Guidelines and Novel Therapies

A Series of Expert Panel Discussions Featuring an Experienced EoE Patient

Hybrid Satellite Symposium during 2022 AAAAI Annual Meeting

Register Today! www.RMEI.com/EoE-Feb-26

Also Available to Virtual Attendees via Online Simulcast

PROGRAM OVERVIEW

Either in-person or virtually by simulcast, please join our multidisciplinary expert panel plus an experienced patient with EoE as they discuss this challenging chronic disease. The panel will address diagnosis and management, as well as pathophysiologic pathways and targets that are currently being explored for its treatment.

Eosinophilic esophagitis (EoE) is a rare, debilitating chronic inflammatory disorder. Unfortunately, diagnostic delay is common and current management approaches do not fully address EoE symptoms or provide endoscopic and histologic resolution. However, several pathophysiologic pathways have been described and targeted therapies are under study for the treatment of EoE.

FACULTY



Matthew Greenhawt, MD, MBA, MSc University of Colorado School of Medicine

 $igodoldsymbol{ extsf{D}}$ chair & panelist



Seema S. Aceves, MD, PhD University of California, San Diego

🎐 SPEAKER & PANELIST



Evan S. Dellon, MD, MPH University of North Carolina School of Medicine SPEAKER & PANELIST

WHO SHOULD ATTEND?

This activity is intended for allergy/immunology physicians, NPs, and PAs who manage patients with EoE.

SATURDAY, FEBRUARY 26, 2022

Reception and Registration: 8:30 PM MST – 8:45 PM MST Symposium and Panel Discussions: 8:45 PM MST – 10:15 PM MST

SHERATON PHOENIX DOWNTOWN:

Phoenix Ballroom C, Third Level

TOPICS TO BE DISCUSSED INCLUDE:

- Overcoming Diagnostic Hurdles in Patients with EoE
- Conventional EoE Management Strategies: Potential Benefits
 and Limitations
- Th2-Driven Inflammatory Processes in EoE: What are the Implications for Future Treatment?

PROVIDER STATEMENT

This educational activity was independently developed by RMEI Medical Education, LLC. All faculty and planner relevant financial relationships were identified and mitigated and RMEI Medical Education, LLC has reviewed the content and determined it to be fair, balanced, and without commercial bias.

DISCLOSURE OF FINANCIAL RELATIONSHIPS

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI will disclose to learners the presence or absence of relevant financial relationships for all persons in control of content before the learner engages in the education.

SUPPORTER STATEMENT

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme.

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact RMEI prior to the live event at contact@rmei.com.

FEE INFORMATION

There is no fee for this educational activity.

REGISTRATION

www.RMEI.com/EoE-Feb-26



This program is not sponsored or programmed by the AAAAI.

November 2021 Board of Directors Meeting Summary

The members of the AAAAI Board of Directors met November 12-14, 2021, in Washington, DC, to discuss current and future activities. Board members also heard presentations from representatives from Hart Health Strategies, the FDA Center for Biologics Evaluation and Research, the FDA Center for Drug Evaluation and Research, and the National Institute of Allergy and Infectious Diseases.

The members of the Board of Directors appreciate the work of AAAAI committee members and chairs as they strive toward the AAAAI mission to advance the knowledge and practice of allergy, asthma and immunology for optimal patient care. Over the course of the meeting, a number of significant decisions and actions were made. Here are the highlights:



The majority of the <u>2021-2022 AAAAI Board of Directors</u>, as well as Executive Vice President Thomas A. Fleisher, MD, FAAAAI, are pictured here in Chicago for the June Board of Directors meeting. Not pictured are Board members Paula J. Busse, MD, FAAAAI, Timothy J. Craig, DO, FAAAAI, Denise A. DiPrimio-Kalman, DO, FAAAAI, and Wanda Phipatanakul, MD, MS, FAAAAI, who joined virtually.

Approvals

A number of requests were granted approval, including the 2022 AAAAI operating budget, the budget to support the work of the Joint Task Force on Practice Parameters, continued funding for The AAAAI Registry and the 2022 Faculty Development Program, and the 2022 AAAAI Foundation operating budget. Beyond funding approvals, the 2022-2023 AAAAI committee appointments and the 2022-2023 Foundation Council Roster, including the addition of five new vicechair positions were also approved.

Presidential Presentations

AAAAI President Giselle S. Mosnaim, MD, MS, FAAAAI, provided further insights on her presidential initiatives, including updates from each of her three presidential task forces: the Community Practitioner Leadership Task Force, Culture of Leadership Task Force, and Disparities Task Force. President-Elect David A. Khan, MD, FAAAAI, provided an updated look at his presidential initiatives for 2022 including his focus on prior authorization, a national residency outreach program, drug hypersensitivity and penicillin allergy delabeling.

Miscellaneous

A number of other projects and topics were discussed, including the selection of Stuart L. Abramson, MD, PhD, AE-C, FAAAAI, as the 2022 At-Large Executive Committee member. The name of the AAAAI CME/ MOC Committee was also changed to the Continuing Certification and Professional Education Committee.

What The next Board of Directors meeting

When February 23-28, 2022 Where Phoenix, AZ

CHANGING THE LIVES OF **BABIES WITH COW'S MILK** ALLERGY



- V Nutramigen[®] can help disrupt allergies
- ✓ **Faster** cow's milk allergy relief today.*^{††} **Fewer** allergy challenges later[§]
- Less crying associated with cow's milk allergy in as fast as 48 hours in 9 out of 10 of your patients*1
- ✓ Reduced eczema and blood in stools in just 4 weeks^{†2,3}
- Helps more babies return to cow's milk in as fast as 6 months^{‡4}
- Reduced future incidence of allergic manifestations including asthma, eczema, rhinoconjunctivitis, and urticaria at three years§5
- #1 brand recommended by pediatricians for cow's milk allergy

PURAMINIO

Choose PurAmino[™] to help support normal growth and development in infants with severe cow's milk allergy and multiple food allergies.

- ✓ PurAmino[™] Infant has **2x the DHA** of EleCare^{®^{II}6,7}
- ✓ DHA and ARA help **support brain and eye development** and may help support the immune system in infancy⁸⁻¹¹
- ✓ PurAmino[™] Jr is the ONLY amino acid-based junior formula that has DHA
- PurAmino Jr has expert-recommended DHA^{¶12,13}





PurAmino has not been shown superior to EleCare in supporting brain, eye, and immune system development in infants.

PurAmino[™] Infant is WIC^{®#}-eligible in 45 states. It is not approved in Alaska, New York, South Dakota, Washington, or Wisconsin.

PurAmino[™] Jr is WIC^{®#}-eligible in 22 states: Alabama, Arizona, California, Florida, Georgia, Idaho, Indiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, New Mexico, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Utah, and Virginia.

Reduced crying in ~90% of infants within 48 hours when managing colic due to cow's milk allergy. Studied before the addition of DHA, ARA, or LGG®**

Reduced eczema (SCORAD index) and blood in stools within 1 month compared to Nutramigen[®] without LGG[®]. Helps more babies overcome cow's milk allergy and return to consuming regular milk proteins in as fast as 6 months of feeding compared to Nutramigen[®] without LGG[®].

Published study showing fewer incidences of asthma, rhinoconjunctivitis, urticaria, and eczema at 3 years compared to Nutramigen® without LGG®. Feeding began at 4 months of age or older in the study.

Province Study and Peccare and Percare an

Elecare is a registere d'ademark of an entity unrelated to Mead Johnson & Company, LLC. References: 1. Lothe L et al. *Pediatrics* 1989;83:262-266. 2. Nermes M et al. *Clin Exp Allergy*. 2011;41:370-377. 3. Baldassarre ME et al. *J Pediatr*.2010;156:397-401. 4. Berni Canani R et al. *J Allergy Clin Immunol*. 2012;129:580-582. 5. Berni Canani R et al. *Clin Immunol*. 2017;139(6):1906-1913. 6. Purkminno Infant Nutrient Profile. Mead Johnson Nutrition; 2017. Accessed May 18, 2020. www.meadjohnson.com/pediatrics/us-en/product-information/products/infants/puramino, 7. EleCare Product Information. Accessed July 13, 2020. https://static.abbottnutrition.com/cms-prod/abbottnutrition-2016.com/img/EleCare.pdf. 8. Birch EE et al. *J Pediatr*. 2010;156:902-906, 9. Birch EE, Carlson SE, Hoffman DR, et al. *Am J Clin Nutr.* 2010;91(4):848-59. 10. Lapillonne A et al. BMC Pediatr. 2014;14:168. 11. Pastor N et al. Clin Pediatr (Phila). 2006;45:850-855. 12. AFSSA (2010). 13. EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA). EFSA J. 2010;8:1461.